CSPC Pharmaceutical Group (HK:1093) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group has entered into an exclusive license agreement with BeiGene for the global development, manufacture, and commercialization of its innovative cancer drug, SYH2039. The deal includes upfront payments of $150 million, with potential milestone payments of up to $1.685 billion, plus royalties. SYH2039, a promising drug targeting MTAP-deficient tumors, has shown strong preclinical results and is currently in Phase I clinical trials in China.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.